

Index to Volume 8

Author Index

- Aaby, P., 138
Acar, J. F., 725, S482
Adelstein, D., 42
Agger, W. A., 927
Ahmed, S., S620
Albrecht, T. B., S434
Anderson, M., S528
Andriole, V. T., 488
Aravantis, D., S579
Arbeit, R. D., 912
Armstrong, D., 1012
Aronoff, S. C., S639
Aronson, S. S., 513, 651, 657, 672
Avlami, A., S579
Aziz, M. A., 500
Baddour, L. M., 117
Baker, A. S., 12, 403
Banks, P. M., 322
Banwell, J. G., S182
Baron, E. J., 771
Barr, C. C., 955
Bartlett, A. V., 539, 663
Bathras, J. M., S396
Bauernfeind, A., S470, S593
Beigel, G., S583
Bennett, W., 295
Bergan, T., S319
Berger, S. A., 747, 756
Bergman, L., S583
Berlin, O. G., 1024
Bibler, M. R., 941
Bisno, A. L., 117
Bitsi, M., S630
Black, R. E., S131
Blaser, M. J., 21, S142
Bloch, M., 306
Block, C., 441
Bluestone, C. D., S617
Blumer, J. L., S639
Bodey, G. P., 959
Brammer, K. W., S589, S612
Bremen, J. G., 454
Brennan, L., S528
Bressler, G. K., 618
Broome, C. V., 568, 584
Bru, J.-P., S612
Brunell, P. A., 589
Brunton, J., 713
Bryan, J. P., 189
Budinger, M. D., S409
Bukh, J., 138
Burgdorfer, W., 932
Burnakis, T. G., 86
Busch, H., Jr., 927
Cabada, F. J., S167
Calder, J. A., 648
Calderone, R. A., 73
Callister, S. M., 927
Cannady, P., Jr., 781
Chandrasekar, P. H., 904
Chao, S.-Y., 984
Charles, D., 411
Chiponis, D., S617
Cho, C. T., 777
Choi, K.-H., S599
Christensen, R. D., S401
Chun, C. H., 955
Cimochowski, C., S528, S535
Clare, D., 713
Cochi, S. L., 568
Cochran, R. K., 952
Cockburn, F., S518
Cogbill, T. H., 927
Cohen, M. L., S117
Cohen, S. L., 441
Cohn, D. L., 21
Collier, A. M., 527
Collins, M. S., S409, S420
Crane, L. R., 364, 374
Crider, L. L., S523
Cummings, G., 364
Cundiff, D. R., 568
Currie-McCumber, C. A., 738
Daikos, G. K., S579
Danila, R. N., 606
Daum, R. S., 558
David, G., 747
Davis, J. P., 613
De Alencar, J. E., 447
Dee, R. R., 968
De Gruttola, V., 295
Deitch, S. R., 669
Denny, F. W., 527
Docampo, R., 884
Domagk, G., 163
Donowitz, M., S188
Dorsey, J. H., S420
Drew, J. S., 447
Drew, W. L., 814
Duez, J.-M., S549
DuPont, H. L., S151, S167, S202, S217
Echeverria, P., S136
Edberg, S. C., 747
Edelman, R., 329, S109
Edwards, J. E., Jr., 73
Eisenberg, E. S., 309
Eklund, A. E., S583
Emerson, T. E., Jr., S409
Emslie, K. R., 841
Engelstein, L., 1036
English, A. R., S528, S535
Ericsson, C. D., S167, S202, S217
Erlich, K. S., S439
Faiella, J., S528, S535
Feldman, H. A., 288
Feris, J., S620
Fiene, R., 634
Finegold, S. M., S569
Fleming, D. W., 568
Foege, W. H., 467
Forcier, G. A., S523
Foster, M. C., S634
Foulds, G., S503
Frantz, N., 42
Fredj, G., S612
Freidig, E. E., 322
Friesen, C. A., 777
Fukushige, J., 874
Galindo, E., S217
Gallagher, P. G., 175
Geddes, A. M., S333
George, W. L., S569
Gerberding, J. L., S315
Giamarelou, H., S579
Giannella, R. A., S223
Giebink, G. S., 533
Gill, F., 54
Gill, V., 54
Gillies, M. L., 50
Gilsdorf, J., 558
Girard, A., S528
Girard, D., S535
Gitch, D. W., 494
Glode, M. P., 631
Gold, B. G., S620
Goldberg, S., 651
Goldberg, S. M., 771
Goldstein, F. W., 725
Goldstein, R. G., 423
Goodman, R. A., 631, 669
Gorbach, S. L., S109
Gottlieb, M. S., 1024
Grady, J. C., 631
Granoff, D. M., 558
Greenhalgh, K., S644
Greenwood, D., S487
Gregory, R. L., 208
Griffin, F. M., Jr., 357
Grosinger, L., 830
Guenin, K., S512
Guerrant, R. L., 213
Hadler, S. C., 548
Hammer, S. M., 427
Hänninen, P., S609
Harmon, S., S620
Harper, T. E., S401
Harrington, G., Jr., 781
Harrison, L. H., 447

- Healy, G. R., 239
 Hector, R. F., S420
 Hedberg, C. W., 699
 Hein, R. H., S374
 Heiner, D. C., S391
 Helgersen, S. D., 568
 Henderson, D. A., 467
 Henderson, F. W., 527, 533
 Heusser, R., S151
 Hildebrandt, N. B., 86
 Hill, H. R., S396, S401
 Hinman, A. R., 573, 660
 Hirsch, M. L., S1
 Hirsch, M. S., 991
 Hisanaga, S., 874
 Hoff, G., 138
 Hoffman, K. L., 12
 Hoffstedt, B., S583, S593
 Höjer, H., S583
 Holm, S. E., S305
 Hopfer, R. L., 959
 Horohov, D. W., 850
 Hoy, J., 959
 Hsu, K.-C., 959
 Huitfeldt, B., S350
 Hull, H. F., 568
 Hutto, C., 599
 Ilstrup, D. M., 792
 Inderlied, C. B., 1024
 Ingelfinger, F. J., 832
 Ingham, H. R., 828
 Ingram-drake, L., S569
 Jacobs, M. R., S639
 Jadavji, T., 397
 John, J. F., Jr., 681, 693
 Johnson, C. C., S569
 Johnson, P. C., S167, S202
 Johnston, L., S569
 Jordan, A. E., 626
 Kager, L., S583
 Kaiser, R. L., 454
 Kalamchi, A., S639
 Kanchanaranya, C., 350
 Kapila, L., S634
 Kaplan, M. H., 771
 Karam, G. H., 357
 Karchmer, A. W., 427
 Karmali, M. A., 397
 Kass, E. H., S1, S465
 Kazmierczak, A., S496, S549
 Kean, B. H., S111
 Keeble, J., S562
 Keefer, C. W., 832
 Kendall, E. D., 651
 Keusch, G. T., 273
 Key, W., S593
 Khan, W. N., S620
 Kim, J.-H., S599
 Kim, Y.-T., S599
 Kingston, M. E., 1
 Kjellgren, K., S583
 Klein, J. O., 513, 521
 Knirsch, A. K., S644
 Kohl, S., S446
 Koyanagi, T., 874
 Krikos, X., S630
 Krohn, K. T., S576
 Krugman, S., 157
 Kuritsky, J., 622
 Labia, R., S496, S549
 Landercasper, J., 927
 Larsen, B., 411
 Lauter, C. B., 830
 Lees, L., S583, S644
 Lelievre, V., S496
 Leuz, W., S593
 Levine, D. P., 364, 374
 Levine, M. M., 329, S207
 Leviton, I., 309
 Lewis, R. B., S434
 Lie, L. A., 669
 Lievens, A. W., 589
 Lindberg, F., S292
 Lindman, J., 648
 Lisse, I. M., 138
 Lode, H., S465
 Löffler, L., S593
 Loo, L. S., S446
 Lorber, B., 968
 Luna, M., 959
 Lundblad, J. L., S382
 Lynch, J. E., S528, S535
 McAllister, T. A., S518
 McClure, S. P., 322
 McCue, J. P., S374
 MacDonald, K., S569
 MacDonald, K. L., 606, S117
 McFarland, L., 548
 Mackey, D., 1
 McLean, A. A., 591
 MacLeod, S., 423
 Maier, M. K., 431, 978
 Makley, J. T., S639
 Malleret, M.-R., S612
 Malmberg, A. S., S583
 Marr, J. J., 884
 Mathisen, G., S569
 Mattioni, D., S496
 Matzke, D. S., S434
 Mayer, K., 295
 Medoff, G., 786
 Meier, M. A., 713
 Micoud, M., S612
 Mills, J., S439, 1001
 Milson, J. A., S644
 Minozzi, C., S482
 Mitra, G., S382
 Mireault, K., 912
 Modlin, J. F., 918
 Moleski, R. J., 488
 Moosdeen, F., S555, S562
 Morand, A., S496
 Morduchowicz, G., 411
 Morgan, G. G., 634
 Morris, D. L., S589, S634
 Muenchow, S., 514
 Mulligan, M. E., S569
 Murphy, T., 558
 Murray, B. E., S172
 Mushinsky, R. F., S523
 Naber, K. G., S604
 Nade, S., 841
 Nadol, J. B., Jr., 403
 Naidu, T. G., 447
 Narula, A. P., 904
 Neu, H. C., 476, S237
 Nicholson, C. A., S523
 Norcia, W., S528
 Nord, C. E., S543, S583
 Nordmann, P., S549
 Normark, S., S292
 Norrby, S. R., S235, S358
 Nyström, G., S583
 Opal, S. M., 781
 Orton, P., 663
 Osterholm, M. T., 513, 558, 606, 672
 Palella, T., 952
 Papadopoulou, B., 725
 Pass, R. F., 599
 Pearson, R. D., 447
 Pechinot, A., S549
 Pennington, J. E., S371, S426
 Petersdorf, R. G., 478
 Peterson, N. J., 618
 Pfeiffer, J. A., 613, 631
 Philipson, A., S583
 Pickering, L. K., 513, 539
 Pier, G. B., S426
 Pierson, C. L., 952
 Pirofsky, B., S457
 Pitlik, S. D., 441
 Pizzarello, R. A., 771
 Pollard, R. B., S434
 Potter, J., 622
 Powderly, W. G., 786
 Pruett, T. L., 829
 Puig, J., S620
 Raff, M. J., 955
 Ravdin, J. I., 247, 261
 Reilly, J. S., S617
 Reinhardt, J. F., S569
 Reller, L. B., 781, 803
 Retsema, J. A., S528, S535
 Reves, R. R., S217
 Reynolds, M. L., S523
 Riebel, W., 42
 Ritch, R., 350
 Robertson, C. S., S589
 Roby, R. E., S420
 Rocha, H., 189
 Rodriguez, R. E., 31
 Rodriguez, W. J., S620
 Rolston, K., 959

- Román, G. C., 760
Román, L. N., 760
Roney, P., 955
Roscoe, M., 397
Rosenfeld, J. B., 441
Rossi, T., S609
Rothstein, G., S401
Rotrosen, D., 73
Rotstein, O. D., 829
Rouan, G. W., 941
Rouse, B. T., 850
Ruane, P., S569
Ruebush, T. K., II, 454
Sack, R. B., S160
Sadoff, J. C., S426
Salata, R. A., 261
Samra, Y., 431, 978
Sande, M. A., S315, 1034
Saraglou, I., S630
Sawyer, P., S528
Schaad, U. B., S512
Schaberg, D. R., 705
Scheld, W. M., 189
Schiff, R. I., S449
Schmid, S., 660
Schmueli, D., 441
Schofield, F., 144
Schroeder, D. D., S382
Scoles, P. V., S639
Scrimshaw, N. S., 273
Sell, T. L., 952
Semel, J. D., 68
Shaked, Y., 431, 978
Shapira, Z., 441
Shapiro, E. D., 622
Sharp, G. W. G., S188
Shih, Y., 984
Shlaes, D. M., 681, 738
Simmons, R. L., 829
Simor, A. E., 397
Sisson, P. R., 828
Skolnik, P. R., 403
Slack, R. C. B., S634
Small, G. J., S426
Smith, H., 651, 657
Smith, N., 505
Smits, A. J., 138
Soave, R., 1012
Soeiro, R., 309
Spagnuolo, P. J., 42
Spink, W. W., 832
Spitzer, P. G., 427
Stahl, J.-P., S612
Stanley, S. L., Jr., 786
Steffen, R., S122, S151
Stephens, K. O., 634, 644
Sternberg, M. M., S382
Sterne, G. G., 660
Sterne, G. S., 644
Stevenson, C. S., 634, 644
Stoloff, A. L., 50
Straehl, P., S512
Sussman, J. I., 771
Sutton, A. M., S518
Swenson, R. M., 809
Syriopoulou, V., S630
Taylor, D. N., S136
Taylor-Wiedeman, J., 589
Teekhasaene, C., 350
Tenold, R., S374
Theodoridis, C., S630
Thoft, R. A., 12
Tokugawa, K., 874
Tomasz, A., S260
Trouvas, G., S579
Tsay, G. C., S420
Tuazon, C. U., 54
Tuomanen, E., S279
Turck, M., 499
Turner, M., 663
Turner, T. L., S518
Twitz, J. A., 693
Tzanetou, K., S630
Ubhi, C. S., S589
Ueda, K., 874
Valero, V., 31
Verghese, A., 912
Vermund, S. H., 423
Vogt, M., 991
Wachsmuth, K., 682
Wald, E., S617
Walsh, J. A., 228
Ward, K. W., S569
Warren, J. W., 61
Warren, M., 454
Washington, J. A., II, 322, 792, 825
Watanakunakorn, C., 31, 175
Watkins, A., 830
Weber, D. J., 12
Wicks, J., S188
Williams, J. D., S555, S562
Wilson, W. R., 322
Wise, R., S325
Wittenberger, R., S604
Woodward, W. E., 539
Yang, I.-S., S599
Young, L. S., S341, 1024
Yussim, A., 441
Zervos, M., 364, 374, 705
Zigler, E., 514

Subject Index

Abortion

- due to *Campylobacter* species, in humans, 397
- therapeutic, first-trimester, prophylaxis for postoperative endometritis, S576

Abscess, brain

- pituitary, 747
- due to *Listeria monocytogenes*, 968
- due to *Salmonella*, 31

Acquired immunodeficiency syndrome

- considerations in child day care, 606
- Cryptosporidium* and cryptosporidiosis, 1012
- epidemiology, underestimation, prevention (editorial), 295
- immunosuppression in, mechanisms, 941
- Mycobacterium avium*-*Mycobacterium intracellulare* disseminated, 1024
- epidemiology, 21
- opportunistic infections, epidemiology, 21
- Pneumocystis carinii* infection, 21, 1001
- prospects for prevention and therapy, 991
- summary and discussion of collection of papers, 1034
- Toxoplasma gondii* infections, 1001
- tuberculosis in, epidemiology, 21

Acute infection, treatment efficacy criteria, S350

Adherence, *Candida*, 73

Adverse effects, to β -lactam antibiotics, S358

Aeromonas, in travelers' diarrhea, S136

AIDS. See Acquired immunodeficiency syndrome

Amdinocillin (mecillinam), prophylaxis for diarrhea, S160

Amebiasis

- diagnosis, epidemiology, morbidity, mortality, 228
- immune mechanisms in humans, 261
- overview, pathogenesis, clinical features, research priorities, 218
- pathogenesis, adherence, toxins, cytolysis of *E. histolytica*, 247
- in U.S., epidemiology, immunology, 239

Aminoglycoside for endocarditis, with penicillin, 54

Aminopenicillins

- with sulbactam, clavulanic acid, or amdinocillin against urinary tract infection isolates, S604
- against urinary tract infection isolates, S604

Amoxicillin, with clavulanic acid against urinary tract infection isolates, S604

Amphotericin B

- intrabursal, for olecranon bursitis due to *P. wickerhamii*, 952
- with oral flucytosine for endogenous aspergillus endophthalmitis, 955

Ampicillin (see also Sulbactam/ampicillin)

- plus chloramphenicol vs. sulbactam/ampicillin for treatment of meningitis in children, S620
- induction/inhibition of chromosomal β -lactamases, S562
- pharmacokinetics in humans, S503
- plus sulbactam or amdinocillin against urinary tract infection isolates, S604

Ampicillin-resistant bacteria, experimental infection with, treatment with sulbactam/ampicillin, S528

Ampicillin/sulbactam. See Sulbactam/ampicillin

Anaerobic bacteria

- gynecologic infections due to, treatment with sulbactam/ampicillin, S579
- identification and susceptibility testing, rationale, 809

β -lactam resistance, S543

sulbactam/ampicillin activity against clinical isolates, S543

Analgesics, injections associated with fever, 68

Angiostrongyliasis, 350

Animal models

- of acute infection due to ampicillin-resistant bacteria, treatment with sulbactam/ampicillin, S528
- of acute hematogenous osteomyelitis, 841
- of fatal systemic infections, treatment with sulbactam/ampicillin, S535

limitations in predicting β -lactam efficacy, S315

of *Mycobacterium avium* complex infection, 1024

Antagonism, between β -lactams and other antibiotics, S305

Antibiotic(s) (see also names of specific agents; Antimicrobial agents)

- β -lactam, interaction with other antibiotics, S305
- combinations, S305
- cost containment in hospitals, 488, 494
- design/development, S260
- interactions, methods for testing, S305
- synergy between β -lactam and other antibiotics, S305

Antibiotic resistance (see also under Plasmids)

in anaerobic bacteria, to β -lactams, S543

β -lactam, S620

due to β -lactamase and diffusion barrier, S292

of endemic pathogens, S172

in *Haemophilus influenzae*, S555

molecular epidemiology, 738

plasmid-mediated in *Haemophilus* species and *N. gonorrhoeae*, 713

plasmid-mediated, introduction to symposium, 681

Antibody-dependent cellular toxicity, against herpes simplex virus, S446

Antimicrobial agents (see also Antibiotic(s); specific antimicrobial agents)

β -lactam, response of bacteria, S487

clinical trials

- in compromised host, S341
- for specific infections, problems, S333
- problems, S333

interactions, techniques for evaluation, S305

pharmacokinetics, evaluation, S319

publication citations, 756

Aortitis, due to *Aspergillus* following coronary artery surgery, 781

Appendicitis, acute, in children, comparison of sulbactam/ampicillin with metronidazole plus cefotaxime, S634

Aspergillois, invasive pulmonary, in immune-normal hosts, 357

Aspergillus

endophthalmitis, endogenous, 955

causing invasive pulmonary disease, 357

Aspergillus clavatus endocarditis, following coronary artery surgery, 781

Aspergillus flavus, in ocular infection of iv drug abusers, 955

Azlocillin, with IgG for treatment of *P. aeruginosa* sepsis in mice, S420

Bacteremia (see also specific pathogen)

in drug addicts, risk factors, epidemiology, therapy, 364

- and endocarditis, in drug addicts, prospective study, 374
due to *Haemophilus influenzae*, in rats, treatment with sulbactam/ampicillin, S535
streptococcal, group A, 941
streptococcal, group B, in men, 912
- Bacteria**
nongrowing, lysis by β -lactam antibiotics, S279
response to β -lactam antibiotics, S487
- Bacterial vaccines**, new, in day care, for prevention of pneumococcal and meningococcal disease, 584
- Bactericidal test**, serum, to monitor therapy for osteomyelitis, endocarditis, controversy regarding usefulness, 803
- Bacteriuria**
antibiotic-resistant, nosocomial, 61
due to *Providencia stuartii*, antibiotic-resistant, 61
- β -lactam antibiotics**
adverse reactions, evaluation, S358
animal models for predicting efficacy, limitations, S315
antagonism with other antibiotics, S305
antibacterial activity, structural effects on, S237
clinical studies, personal experience, S333
clinical trials, problems associated, S333
comparative trials, S333
evaluation, symposium, S235-S270
interaction with other antibiotics, S305
introduction to and summary of symposium, S235
lysis of nongrowing bacteria, S279
mathematical models of tissue penetration, S325
mechanism of action, S260
new activity, S279
resistance
in anaerobic bacteria, mechanisms, S543
due to chromosomal β -lactamases, S292
role of β -lactamases in gram-negative bacilli, S482
response of bacteria, S487
safety evaluation, problems, S333
structural relationships affecting in vitro and pharmacologic properties, S237
synergy with other antibiotics, S305
in systemic infections, review of experience, S333
tissue penetration, evaluation, including in vitro and animal models, S325
- β -lactamase(s)**
in *Bacteroides*, S543
chromosomal
induction/inhibition by β -lactamase inhibitors, S562
resistance due to, regulation, overproduction, induction, S292
classification, S470
in clostridia, S543
in fusobacteria, S543
in gram-negative bacilli, role in resistance, S482
inhibition by sulbactam, biochemical factors, S496
inhibitors, induction/inhibition of β -lactamases, S562
synthesis, mechanism of inducible and constitutive, S292
- Biliary pharmacokinetics**, in humans, of sulbactam/ampicillin, S589
- Bismuth subsalicylate**
in prevention of travelers' diarrhea, S151
for treatment of travelers' diarrhea, S202
- Bite injury**, infection with *Eikenella corrodens*, 50
- Blood cultures**, for detection of septicemia, 792
- Bone and joint infections**
in children, sequential treatment with sulbactam/ampicillin and oral sultamicillin, S639
in iv drug abusers, 904
sulbactam/ampicillin vs. cefotaxime for treatment, S593
- Borrelia burgdorferi*, causative agent of Lyme disease and related disorders, 932
- Borreliae*, cultivation, 932
- Botulism**, in China, 984
- Brain abscess**. See Abscess, brain
- Bursitis**, protothecal olecranon, 952
- Campylobacter jejuni* enteritis, treatment, S207
- Campylobacter* species, maternal infection associated with human abortion and perinatal infection, 397
- Candida* species, adherence, nosocomial infections, and pathogenesis, 73
- Canine distemper virus**, immunosuppression due to, 941
- Case report(s)**
abortion and perinatal sepsis due to *Campylobacter*, 397
aspergillus endocarditis following coronary artery surgery, 781
fever with repeated analgesic injections, 68
lactobacillus endocarditis, 771
Haemophilus influenzae, type b, neonatal sepsis and non-type b neonatal sepsis, 777
nosocomial device-related infection due to *Corynebacterium JK*, 42
pneumococcal endocarditis, 786
pulmonary aspergillosis in immune-normal hosts, 357
rhinocerebral mucormycosis in renal transplant recipients, 441
salmonella intracranial infections, 31
salmonellosis, nontyphoid, in renal transplant recipients, 431
streptococcal, group B, endocarditis, 175
taeniasis unresponsive to single-dose therapy, 423
toxic shock syndrome, annotated bibliography, S77-S101
trimethoprim-sulfamethoxazole treatment of *L. monocytogenes* infection, 427
tuberculosis of the middle ear, 403
- Catheters**, indwelling, urinary, infection with antibiotic-resistant *P. stuartii*, 61
- Cefotaxime**
for soft tissue and bone and joint infections S593
plus metronidazole vs. sulbactam/ampicillin for acute appendicitis in children, S634
- Cefoxitin**, induction/inhibition of chromosomal β -lactamases, S562
- Cephalosporinases**, in *B. fragilis*, S543
- Cephalosporins**
adverse reactions, S358
for pelvic inflammatory disease, 95
- Cervical adenitis**, due to ampicillin- or penicillin-resistant organisms in children, treatment with sulbactam/ampicillin, S630
- Chagas' disease**, chemotherapy and considerations of future research on therapy, 884
- Chemotherapy**, for bacterial infections, classic paper, 163
- Chickenpox**, exclusion from day care of children, ineffectiveness of control, vaccine, 589
- Children**. See Pediatric infections; Pediatric patients; *specific infection*
- Chlamydia trachomatis*, causing pelvic inflammatory disease, 86
- Chloramphenicol**, for intracranial salmonella infection, 31

- Chloramphenicol/ampicillin, vs. sulbactam/ampicillin for treatment of meningitis in children, S620
- Cholera
epidemiology in travelers, S122
treatment, S207
- Clavulanic acid, induction/inhibition of chromosomal β -lactamases, S562
- Clindamycin, vs. sulbactam/ampicillin for bacterial infections, S569
- Clinical trials
efficacy criteria, S350
in immunocompromised host, S341
of prophylaxis in immunocompromised hosts, S341
sample size, S350
statistical aspects for acute infections, S351
therapy in immunocompromised hosts, S341
- Classic papers
on bacteremia, significance of hemolytic streptococci, 832
chemotherapy for bacterial infections, 163
necrosis, pathology and treatment, 505
- Clostridium botulinum*, in outbreaks of botulism in China, 984
- Clostridium difficile*, diarrhea and colitis, treatment, S207
- Combination therapy (see also specific drug names)
for pelvic inflammatory disease, 86
vs. single agent for endocarditis, 54
- Compromised host. See Immunocompromised patients
- Controversies, diagnosis and management of infectious diseases, collection of papers
AIDS, 991-1035
diagnosis, 792-827
reimbursement for health care, 478-499
- Corn-harvesting machines, infection in wounds, 927
- Corynebacterium* JK, causing nosocomial device-related infection, 42
- Cost containment
of antibiotics, role of infectious disease specialist, 488, 494
effect on practice and training of infectious disease specialists, 478
- Cryptosporidiosis, in AIDS and other immunocompromised patients, 1012
- Culture, viral, usefulness, 814
- Cysticercosis, 350
- Cytomegaloviral infection, in child day care, prevalence, risk, recommendations, 599
- Cytomegalovirus, in vitro sensitivity to antibody, S434
- Cytomegalovirus-neutralizing antibody, in IgG preparations, S434
- Day care, child
cytomegaloviral infections of mothers, children, and workers, 599
demographics, 514, 672
design of environment to prevent infection, 521, 618, 672
diarrhea, infectious acute, 539
effects on children, 514
employees
cytomegaloviral infection risk to women, 599
education and training, 521, 634, 651, 672
health, 573, 599, 644
workers' compensation, 644
epidemiology of infections, 521, 622
exclusion for illness, 589, 622, 626, 634
gastrointestinal infections, 521, 539
"get-well" centers, 626
Haemophilus influenzae type b infections, 558, 568
health benefits, 660
hepatitis, A and B, 548, 591
HTLV-III/LAV virus, considerations for transmission and recommendations, 606
infection control specialist, role, 631
infectious diseases, symposium on management and prevention, 513-679
liability for infectious diseases, 644, 672
licensing and regulation, 514, 521, 634, 672
management of infectious diseases, 521, 573, 626, 631, 634, 651, 672
medication, storage and administration, 521, 657
otitis media, epidemiology and pathogenesis, 533
overview, 514, 521
psychological benefits, 514
quality assurance, 514, 634
recommendations of the symposium, 672
regulations, licensing, 514, 521, 634, 672
resources for providers, 648
respiratory infections, acute, 527
summary of symposium, 672
surveillance of disease, 613
transmission of infection, 521
types, 514, 672
vaccine-preventable diseases, 573
varicella, 589
- Day care homes, 663
- Developing countries (see also Primary health care, in developing countries)
travelers' diarrhea, S142
- Diagnosis
of clinical disease by lymph node biopsy, 322
of life-threatening infection, skin clues, 1
viral, usefulness, 814
- Diagnosis-related groups, impact on infectious disease practice, 494
- Dialysis, peritoneal, fungal infection, 309
- Diarrhea
acute, in child day care, microbial causes, environmental factors, incidence, transmission, control, 539
bacterial, treatment, S207
control of in developing countries, effect on nutrition, 273
infectious, antimicrobial therapy, S207
protozoal, treatment, S207
of travelers. See Travelers' diarrhea
- Diethylcarbamazine, in treatment of onchocerciasis, 500
- Diphtheria, immunization, 573
- Disseminated intravascular coagulation, in skin lesions due to infection, 1
- DNA, restriction endonuclease digestion patterns, 682
- Domagk, Gerhard, classic paper on chemotherapy for bacterial infections, 163
- Doxycycline, prophylaxis for travelers' diarrhea, S160
- DRGs, impact on infectious disease practice, 494
- Drug abusers
bacteremia, microbiology, epidemiology, risk factors, therapy, 364
bone and joint infections, 904

- fungal endophthalmitis, 955
infectious endocarditis, prospective study, 374
- Echovirus infection, nursery outbreaks among newborns, 918
- Ecthyma gangrenosum, histology and cause, 1
- Eikenella corrodens*
in bite and fist-fight injuries, 50
isolation using selective medium, 50
in vitro susceptibility testing, 50
- Empiric therapy, for bacteremia in drug addicts, 364
- Encephalitis, experimental, due to herpes simplex virus, treatment with specific antibody, S439
- Endocarditis
due to *Aspergillus*, following coronary artery surgery, 781
infections, in drug addicts, prospective study, 374
infective, complicating mitral valve prolapse, 117
 β -lactam efficacy, limitations of animal models in predicting, S315
due to lactobacilli, therapy, 771
pneumococcal, 786
staphylococcal, in rats, treated with sulbactam/ampicillin, S535
due to streptococci
group B, 175
treatment, 54
- Endometritis, prophylaxis of in first-trimester abortion, S576
- Endophthalmitis
endogenous, due to *Aspergillus*, 955
following intraocular lens implantation, 12
- Entamoeba histolytica*
detection methods, 228
disease syndromes, asymptomatic, symptomatic, extraintestinal, 218
immune mechanisms, humoral and cellular, in vitro and in patients, 261
immunodiagnosis and antigen detection, epidemiology in United States, 239
pathogenesis, biology, adherence, secreted toxins, contact-dependent cytotoxicity, 247
- Enteric disease
prevention, S227
workshop on typhoid fever, 329-349
- Enteric pathogens, resistance to antibiotics, S172
- Enterobacteria, gram-negative, β -lactam resistance, S292
- Enterobacteriaceae, plasmid analysis of trimethoprim resistance, 725
- Enteropathogenic infections, in travelers, S227
- Epidemiology
of antibiotic resistance in *H. influenzae*, S555
molecular
of antibiotic-resistance plasmids of *Haemophilus* species and *N. gonorrhoeae*, 713
of gram-negative bacteria, 693
of gram-positive nosocomial cocci, 705
of *Salmonella*, *Vibrio*, and *E. coli*, 682
symposium, 681-746
trimethoprim resistance in Enterobacteriaceae, 725
usefulness of plasmid analysis, summary, 738
- Epiglottitis, acute, in children, treatment with sulbactam/ampicillin, S617
- Escherichia coli*
enterohemorrhagic, antimicrobial therapy for infections, S207
enteroinvasive, antimicrobial therapy for infections, S207
enteropathogenic, antimicrobial therapy for infections, S207
enterotoxigenic, antimicrobial therapy for infections, S207
enterotoxigenic, and travelers' diarrhea, S131
prevention with antimicrobial agents, S167
prevention with nonantibiotic drugs, S151
treatment with trimethoprim, trimethoprim-sulfamethoxazole, bicozamycin, or furazolidine, S217
immunoglobulin G, intravenous, native pH 4.25, activity, S396
- Erythromycin, prophylaxis for travelers' diarrhea, S160
- Family day care homes, 663
- Fever, associated with analgesic injections, 68
- Flora, normal, role of group A *Streptococcus*, 941
- Flucytosine
with amphotericin B (intravitreal) for endogenous aspergillus endophthalmitis, 955
for fungal peritonitis in peritoneal dialysis patients, 309
- 5-Fluorocytosine. See Flucytosine
- Food-borne infections, environmental interventions, S142
- Fungal infections
diagnosis by lymph node biopsy culture, 322
Trichosporon beigelii, 959
- Fungal peritonitis, in peritoneal dialysis patients, 369
- Gastrointestinal infections, severe, epidemiology in travelers, S122
- Genetic methods, plasmid profiles, hybridization, 682
- Gentamicin, plus clindamycin vs. sulbactam/ampicillin for intraabdominal infections in surgical patients, S583
- "Get-well" day care facilities, 628
- Gnathostomiasis, 350
- Gram-negative bacilli
resistance to β -lactam antibiotics, role of β -lactamases, S482
response to β -lactam antibiotics, S487
in wounds caused by corn-harvesting machines, 927
- Gram-negative bacteria
 β -lactamases, chromosomal, induction/inhibition by β -lactamase inhibitors, S562
causing nosocomial infection, plasmids, 693
- Gram-positive cocci
plasmid analysis in, epidemiology, 705
response to β -lactam antibiotics, S487
- Gynecologic infections (see also Obstetric infection; Pelvic infection; Pelvic inflammatory disease)
treatment with sulbactam/ampicillin, S579
- Haemophilus influenzae*
antibiotic resistance, S555
bacteremia and meningitis in infant rats, treatment with sulbactam/ampicillin, S535
epiglottitis, treatment with sulbactam/ampicillin, S617
meningitis in children, treatment with sulbactam/ampicillin vs. chloramphenicol/ampicillin, S620
neonatal sepsis due to type b and non-type b, 777
serotypes, 777
type b, epiglottitis, treatment with sulbactam/ampicillin, S617
type b, in child day care
chemoprophylaxis with rifampin, 521, 558, 568
immunization, 558, 568
incidence, 558
recommendations, 568

- respiratory infections, 521
- risk, 559, 568
- Haemophilus* species, plasmid analysis of antibiotic resistance, 713
- Hand washing, to control infection in child day care, 521, 618, 634
- Health priorities, management, in developing countries, 467
- Hepatitis, Willowbrook studies, retrospective, 157
- Hepatitis A, in child day care
 - epidemiology and prevention, 548
 - vaccine development, 591
- Hepatitis B, in child day care
 - epidemiology and prevention, 548
 - model for HTLV-III, 606
 - vaccine development, 591
- Hepatitis non-A, non-B, in child day care, theoretical risk, 548
- Herpes simplex virus
 - antibody-dependent cellular toxicity of immunoglobulin G iv preparations, S446
 - encephalitis in mice, treatment with specific antibody, S439
- Herpesviruses, immunosuppression by, mechanisms, 941
- Historical articles, syphilis, 19th-century attitudes, 1036
- HIV (human immunodeficiency virus). *See* HTLV-III/LAV; AIDS
- Hospital management, under DRGs, relation to infectious disease practice, 494
- Host immunity, to *E. histolytica*, 261
- HTLV-III/LAV
 - in child day care, risk of transmission and recommendations, 606
 - immunosuppression by, mechanisms, 941
 - infection, prevention and therapy of infections, 991
- Hypothesis, cross-sex transmission of measles and increased mortality, 138
- Human T-lymphotropic virus type III/lymphadenopathy-associated virus. *See* HTLV-III/LAV
- IgA deficiency, IgG subclasses in, S391
- IgG. *See* Immunoglobulin G
- Illness, in child day care
 - employment policies, 626
 - exclusion from day care, 622, 626, 634, 672
 - on-site care, in-home care, "get-well" centers, infirmity care, satellite group care, recommendations, 626
- Immune-mediated skin lesions, associated with septicemia, 1
- Immunization
 - for control of tetanus in developing countries, 144
 - against experimental *P. aeruginosa* pneumonia with detoxified lipopolysaccharide vaccine, S426
 - passive, for *P. aeruginosa* pneumonia in guinea pigs, S426
- Immunocompromised patients
 - clinical trials, problems associated, S341
 - Cryptosporidium* and cryptosporidiosis, 1012
 - treatment of infection, S341
- Immunodeficiency disease, primary, therapy with IgG intravenous preparations, S457
- Immunodeficiency, humoral, therapy with IgG intravenous preparations, S449
- Immunoglobulin A deficiency, IgG subclasses in, S391
- Immunoglobulin G, preparations for clinical use, physical and functional properties, S374
- Immunoglobulin G, intravenous preparations
 - with antibiotic in therapy for *P. aeruginosa* infection and sepsis in mice, S420
 - anticomplement activity, S382
 - Cohn fraction II, S382
 - cytomegalovirus-neutralizing antibody in, methods of selection and assessment of presence, S434
 - half-life, S449
 - for herpes encephalitis experimental infection, S439
 - against herpes simplex virus, by antibody-dependent cellular toxicity tests in vitro and in vivo, S446
 - hyperimmune, for passive immunization against *P. aeruginosa* infection in guinea pig model, S426
 - in immunodeficiency disease, S449
 - for immunodeficiency, primary, S457
 - impurities in different preparations, S382
 - introduction and summary of symposium on new, native preparations, S371
 - native, pH 4.25
 - activity against bacterial pathogens, S396
 - effect on neutrophil kinetics in experimental model, S401
 - effect of rapid infusion in animal model of *S. typhimurium* bacteremia, S409
 - neutralization of exotoxin A in mice, S420
 - opsonic activity, S396
 - pharmacokinetics, S449
 - protective activity, S396
 - protein aggregates, S382
 - safety and toxicity, S457
 - specific antibody content, S391
 - subclass composition and clinical relevance, S391
 - symposium, S371-463
- Immunoglobulin G, preparations for clinical use, physical and functional properties, S375
- Immunosuppression
 - suppressor molecules, 941
 - due to viral infection, examples and mechanisms, 941
- Incidence, in child day care
 - acute diarrhea, 539
 - acute respiratory infections, 527
 - Haemophilus influenzae* type b infections, 558, 568
 - hepatitis, 548
 - illness in group vs. home care, 521
 - infectious diseases, 521
 - otitis media, 533
- Infection(s)
 - acute, clinical trials of antibiotics, S350
 - role in malnutrition, 273
- Infection control, in child day care
 - hand washing, 521, 618, 634
 - role for specialists, 631
- Infectious disease specialists
 - in day care, 631
 - excessive numbers, 478
 - role in cost containment of antibiotics, 488, 494
- Influenza, immunization, 573
- Injection fever, 68
- Intraabdominal infections, treatment with sulbactam/ampicillin vs. gentamicin plus clindamycin, S583
- Intracranial infection, focal, due to *Salmonella*, 31
- Intraocular lenses, endophthalmitis following implantation, 12
- Intrauterine devices, removal, in pelvic inflammatory disease, 86
- Ivermectin, for treatment of onchocerciasis, 500

- Klebsiella pneumoniae*, IgG native, pH 4.25, activity, S396
- Lactobacillus* species, causing endocarditis, 771
- Liability, for infectious diseases in child day care, 644, 672
- Leishmania donovani*, and under nutrition, 447
- Leishmaniasis, visceral, reciprocal relationship between under-nutrition and disease, hypothesis, 447
- Lipopolysaccharide vaccines, in experimental model of *P. aeruginosa* pneumonia, S426
- Listeria monocytogenes*
causing brain abscess, 968
treatment of infection with trimethoprim-sulfamethoxazole, case report, 427
- Lymph node biopsy, correlation with histopathologic and microbiologic findings with clinical disease, 322
- Lymphocyte function, effect of viral infection, 941
- Macrophages
effects of viruses on defense functions and role in acquired immunodeficiency, 941
immunosuppression due to change in function, 941
- Malaria
biology, epidemiology, treatment, 454
control in developing countries, 454
- Malnutrition, childhood, prevalence and relation to infection, control of, 273
- Mastoiditis, tuberculous, 403
- Measles
cross-sex transmission and increased mortality, 138
immunization in day care, 573
immunosuppression, 941
- Mecillinam. See Amdinocillin
- Medication, storage and administration in day care, 521, 657
- Membrane permeability, interaction with chromosomal β -lactamases in β -lactam resistance, S292
- Meningitis
bacterial, penetration of sulbactam in patients with, S612
 β -lactam efficacy, limitations of animal models in predicting, S315
in children of day care age, and polysaccharide vaccine, 584
in children, due to *H. influenzae*, *H. pneumoniae*, and *N. meningitidis*, treatment with sulbactam-ampicillin vs. chloramphenicol/ampicillin, S620
due to *H. influenzae* in rats, treatment with sulbactam/ampicillin, S535
neonatal, due to *H. influenzae*, 777
pharmacokinetics of sulbactam and ampicillin in patients, S503
due to *Salmonella*, treatment, 189
sulbactam penetration into CSF of patients with inflammation due to viral, S609
- Meningococcal disease, in children in day care
chemoprophylaxis, 521, 558, 568, 584
meningitis, 584
respiratory, 521
risk in day care, 584
- Meningococcus
sulfadiazine, susceptibility and resistance, historical perspective, 288
surveillance studies, 288
20-year perspective, special article, 288
- Metabolism, and infection, effect on nutritional status, 273
- Metronidazole, plus cefotaxime vs. sulbactam/ampicillin for acute appendicitis in children, S634
- Microbiology, of infections in day care, 521, 618
- Mitral valve prolapse, complicated by infective endocarditis, 117
- Molecular epidemiology. See Epidemiology, molecular
- Mucormycosis, rhinocerebral, in renal transplant recipients, 441
- Mumps, immunization, 573
- Mycobacterial infection
in AIDS, 1024
diagnosis by lymph node biopsy culture, 322
- Mycobacterium avium* complex
in AIDS, 1024
animal model, 1024
in vitro susceptibility, 1024
- Mycobacterium tuberculosis*, causing otitis media, mastoiditis, 403
- Mycoplasma hominis*, causing pelvic inflammatory disease, 86
- Myelopathies, tropical, etiology, 760
- Narcotic addicts. See Drug abusers
- Neisseria gonorrhoeae*
penicillinase-producing, treatment of infection with sulbactam/ampicillin plus probenecid, S599
and pelvic inflammatory disease, 86
plasmid analysis of antibiotic resistance, 713
- Neisseria meningitidis*. See Meningitis; Meningococcal disease; Meningococcus
- Neonatal infection
due to echovirus, 918
sepsis due to *H. influenzae*, 777
- Neonates
preterm, pharmacokinetics of sulbactam and ampicillin, S503, S518
term, pharmacokinetics of sulbactam/ampicillin, S518
- Neutropenic patients, clinical trials, problems associated, S341
- Neutrophils, kinetics during experimental group B streptococcal infection, S401
- Niclosamide, for taeniasis, 423
- Nosocomial infection
Candida species, 73
Corynebacterium JK, device-related, 42
endophthalmitis following intraocular lens implantation, 12
gram-negative bacteria, plasmid analysis, 693
gram-positive cocci, plasmid analysis, 705
Providencia stuartii bacteremia, 61
- Nutritional status, effect on infection, 273
- Obstetric infection, due to *Streptococcus* group A and B, 411
- Occupational injuries, infection due to corn-harvesting and industrial equipment, 927
- Ocular infection
parasitic, in Thailand, 350
onchocerciasis, therapy, 500
- Olecranon bursitis, due to *P. wickerhamii*, treatment with amphotericin B, 952
- Onchocerca volvulus*, chemotherapy for infection, editorial, 500
- Onchocerciasis, chemotherapeutic approach, editorial, 500
- Opportunistic infections, in AIDS, epidemiology, 21
- Ornithodoros coriaceus*-borne *Borrelia*, as possible cause of epizootic bovine abortion, 932
- Osteomyelitis
acute hematogenous, pathogenesis and treatment, with ref-

- erence to animal model, 841
 in children, sequential treatment with parenteral sulbactam/ampicillin and oral sultamacillin, S639
 classic paper by Nathan Smith, 505
 due to *Salmonella*, treatment, 189
- Otitis media**
 epidemiology and pathogenesis in day care, 533
 penetration of sulbactam in middle-ear fluid of children with infection, S503
 tuberculous, case report, 403
- Parasitic infection**
 ocular, in Thailand, 350
 relation to undernutrition in visceral leishmaniasis, 447
- Parvoviruses**, immunosuppression by, 941
- Passive immunization** (see also under Immunoglobulin G, intravenous preparations)
 for *P. aeruginosa* pneumonia in guinea pigs, S426
- Pathogenesis**, of *Candida* species, 73
- Pediatric infections**
 due to ampicillin- or penicillin-resistant organisms, treatment with sulbactam/ampicillin, S630
 bone and joint, sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin, S639
 meningitis, sulbactam/ampicillin vs. chloramphenicol/ampicillin for treatment, S620
- Pediatricians**, relation to day care, 669, 672
- Pediatric patients**, pharmacokinetics of single iv dose of sulbactam, S512
- Pelvic infection** (see also Gynecologic infection; Obstetric infection; Pelvic inflammatory disease)
 puerperal sepsis, due to *Streptococcus* group A and B, 411
- Pelvic inflammatory disease**
 epidemiology, diagnosis, treatment, 86
 sequelae, 86
 treatment with cephalosporins, 86
 treatment with tetracyclines, 94
- Penicillanic acid sulfone**. See Sulbactam
- Penicillin** (see also Penicillins)
 for endocarditis due to group B streptococci, 175
 high-dose treatment for lactobacillus endocarditis, 771
- Penicillinases**
 in clostridia, S543
 in fusobacteria, S543
 in nonfragilis *Bacteroides*, S543
- Penicillin-binding proteins**
 in anaerobic bacteria, S543
 affinity of sulbactam, S496
 review, S260
- Penicillins**
 adverse effects, S358
 for endocarditis, alone and in combination with aminoglycoside, 54
 for pelvic inflammatory disease, 86
- Perinatal infection** (see also Neonatal infection; Neonates)
 due to echovirus 918
- Peritonitis**, fungal, in peritoneal dialysis patients, 309
- Pertussis**, immunization, 573
- Pharmacokinetics**
 biliary, in humans, of sulbactam/ampicillin, S589
 evaluation of antibiotic, including Phase I studies, S319
 in newborn, of sulbactam/ampicillin, S518
 requirements for antibiotics, S319
 of sulbactam in pediatric patients, S512
 of sulbactam/ampicillin, S503
- Pituitary gland**, infection, 747
- Plaque-reduction method**, for determination of neutralizing antibody, S434
- Plasmids**
 analysis of antimicrobial-resistant gram-positive cocci, 705
 antibiotic resistance, of *Haemophilus* species, 713
 antibiotic resistance, of *N. gonorrhoeae*, 713
 as epidemiologic markers of gram-negative bacteria, 693
 as epidemiologic markers of gram-positive bacteria, 705
 for epidemiologic typing of organisms, 738
 epidemiology, introduction to symposium, 681
 epidemiology of trimethoprim resistance, 725
 of *Escherichia coli*, profile, 682
 R, epidemiology, 738
 of *Salmonella*, profile, 682
 of *Vibrio*, profile, 682
- Plasmodium**. See Malaria
- Pneumococcus**. See *Streptococcus pneumoniae*
- Pneumocystis carinii**, infection, diagnosis and treatment in patients with AIDS, 1001
- Pneumonia**
 in AIDS patients, evaluation, 1001
 due to ampicillin- or penicillin-resistant organisms, treatment with sulbactam/ampicillin, S630
 due to *Aspergillus*, 357
- Poliomyelitis**, in child day care, immunization, OPV, 573
- Polymicrobial infections**
 animal models, treatment with sulbactam/ampicillin, S528
 treatment with sulbactam/ampicillin vs. clindamycin, S569
- Praziquantel**, for taeniasis, 423
- Pregnancy**, pharmacokinetics of sulbactam and ampicillin, S503
- Primary health care**, in developing countries
 control of infection to reduce prevalence of infantile and childhood malnutrition, 273
 malaria, 454
 management priorities, 467
 tetanus, 144
- Probes**, DNA, RNA hybridization of bacterial specimens, 682
- Prophylaxis**
 for travelers' diarrhea, antibiotic, S160, S167
 for travelers' diarrhea, nonantibiotic, S151
 with sulbactam/ampicillin for endometritis following first-trimester abortion, S576
- Prospective payment system**, 494
- Prosthetic valve endocarditis**, 771
- Prototheca wickerhamii**, in olecranon bursitis, treatment with amphotericin B, 952
- Providencia stuartii**, causing nosocomial bacteriuria, 61
- Pseudomonas**, in bacteremia, therapeutic trials, S341
- Pseudomonas aeruginosa**
 hyperimmune IgG, intravenous, for immunization, S426
 IgG, intravenous, native pH 4.25, activity, S396
 infection in neutropenic mice, S420
 lipopolysaccharide vaccine for pneumonia in mice, S426
 pneumonia in guinea pigs, passive immunization, S426
- Puerperal sepsis, due to *Streptococcus* group A and B, 419
- Purpura, due to septicemia, 1

- Reimbursement for health care, summary of panel, 499
- Resistance. *See* Antibiotic resistance
- Respiratory infections, in child day care
- acute, 527
 - otitis media complicating, 533
- Rhizopus arrhizus*, rhinocerebral infection in renal transplant recipients, 441
- Ribosomal vaccines, structure, immunology, uses, 208
- Rifampin, chemoprophylaxis in child day care
- for *Haemophilus influenzae* type b infection, 521, 558, 568
 - for meningococcal disease, 584
- Rotavirus, in day care, causing gastrointestinal infection, 521
- Rubella, congenital syndrome, physical growth in affected children, 874
- Russia, syphilis in, 1036
- Salmonella* (*see also* Salmonellosis)
- in AIDS, epidemiology, 21
 - in chronic carrier state, treatment, 189
 - focal intracranial infection, 31
 - gastroenteritis, treatment, S207
 - nontyphoid, in renal transplant recipients, case report, 431
 - resistance to antibiotics, S172
 - in travelers' diarrhea, S136
- Salmonella typhi*, in Workshop on Typhoid Fever, 329-349
- Salmonella typhimurium*
- bacteremia, prophylaxis and treatment with native IgG in animal model, S409
 - peritonitis, treatment with native immunoglobulin G preparation in animal model, S409
- Salmonellosis
- in total hip replacement, 978
 - treatment with β -lactams and quinolones, 189
- Salpingitis, diagnosis, 86
- Sella turcica, infection, 747
- Sepsis
- neonatal, due to *H. influenzae*, 777
 - perinatal, and abortion in humans, due to *Campylobacter*, 397
- Septic arthritis, in children, sequential treatment with sulbactam/ampicillin and oral sulfamethoxazole, S639
- Septicemia
- detection by blood culture, 792
 - skin lesions associated with, 1
- Serratia marcescens*, IgG, native pH 4.25, activity against, S396
- Serum bactericidal test, to monitor therapy for osteomyelitis, endocarditis, controversy regarding usefulness, 803
- Sexually transmitted disease, pelvic inflammatory, epidemiology, diagnosis, treatment, 86
- Shigella*
- in day care, causing gastrointestinal infection, 521
 - resistance to antibiotics, S172
- Shigellosis, treatment, S207
- Side effects. *See* Adverse effects
- Simulium* species, control, 500
- Skeletal infections, in iv drug abusers, 904
- Skin infections, in day care, 521
- Skin lesions
- of *Candida* septicemia, 1
 - as diagnostic clues to life-threatening infection, 1
 - immune-mediated, 6
 - disseminated, intravascular coagulation, 1
 - of rickettsial infection, 5
 - of staphylococcal septicemia, 2
- Smith, Nathan, classic paper on osteomyelitis, 505
- Soft tissue infections, sulbactam/ampicillin vs. cefotaxime for treatment, S593
- Spirochetoses, tick-borne, changing research interest, 932
- Staphylococcus aureus*
- methicillin-resistant, bactericidal activity of sulbactam/ampicillin in vitro, S549
 - methicillin-resistant in bone and joint infections in iv drug abusers, 904
 - as pathogen in endophthalmitis, 12
- Staphylococcal infection, animal model of thigh infection treated with sulbactam/ampicillin, S535
- Staphylococci
- methicillin-resistant in drug abusers, 364
 - plasmid analysis in epidemiology of nosocomial isolates, 705
- Staphylococcus epidermidis*, as pathogen in endophthalmitis, 12
- Statistics, aspects in clinical trials of antibiotics for acute infections, S350
- Streptococcus*
- in endocarditis, 54
 - group A
 - in bacteremia, 941
 - infections in day care, 521
 - in normal flora, 941
 - in puerperal sepsis and obstetric infections, historical perspective, 411
 - in bone and joint infections in iv drug abusers, 904
 - group B
 - in bacteremia in men, 912
 - in endocarditis, 175
 - experimental infection, effect of IgG, intravenous, S401
 - penicillin susceptibility, 175
 - in puerperal sepsis and obstetric infections, historical perspective, 411
 - group G, in bone and joint infections in iv drug abusers, 904
- Streptococcus mutans*, ribosomal vaccine, 208
- Streptococcus pneumoniae*
- in child day care
 - chemoprophylaxis, 573
 - meningitis, 584
 - otitis media, 584
 - respiratory infection, 521
 - risk of infection, 584
 - vaccine, polysaccharide, 584
 - in endocarditis, 786
- Streptococcus pyogenes* bacteremia, 941
- in drug addicts, 364
- Sulbactam (*see also* Sulbactam/ampicillin)
- and ampicillin, synergy, S496
 - β -lactamase inhibition, mechanisms, S496
 - induction/inhibition of chromosomal β -lactamases, S562
 - penetration into CSF, S609
 - of patients with bacterial meningitis, S612
 - pharmacokinetics, S503
 - in pediatric patients, S512
 - stability in diluents for parenteral administration, S523
- Sulbactam/ampicillin (*see also* Sulbactam)
- activity in vitro against clinical strains, S528
 - activity against methicillin-resistant isolates, S528

- for aerobic-anaerobic infections, S569
- in animal models of infection, S529
 - due to ampicillin-resistant organisms, S535
- bactericidal activity against methicillin-resistant *S. aureus*, S549
- biliary pharmacokinetics, S589
- vs. cefotaxime in initial therapy for soft tissue and bone and joint infections, S593
- for cervical adenitis due to ampicillin- or penicillin-resistant organisms in children, S630
- vs. chloramphenicol/ampicillin for meningitis in children, S620
- vs. clindamycin for aerobic or mixed aerobic-anaerobic infections, S569
- distribution into plasma and extravascular fluid in mice, S535
- for epiglottitis in children, S617
- vs. gentamicin/clindamycin for intraabdominal infections, S583
- for gonorrhea due to penicillinase-producing organisms, with probenecid, S599
- for gynecologic infections, S579
- introduction to and summary of symposium, S465
- for meningitis, S612
- vs. metronidazole plus cefotaxime for acute appendicitis in children, S634
- pharmacokinetics, S503
 - in children with bacterial meningitis, S620
 - in neonates, S518
- for pneumonia due to ampicillin- or penicillin-resistant organisms in children, S630
- as prophylaxis
 - in first-trimester abortion, S576
 - review of efficacy and safety in clinical trials, S644
- in screening and discriminative models of infection, S535
- for skeletal infections in children, sequentially with oral sulfamethoxazole, S639
- spectrum and activity in vitro, S528
- stability in diluents for parenteral administration of ampicillin, S523
- synergy
 - against clinical isolates, S528
 - biochemical factors involved, S496
 - therapy, review of efficacy and safety in clinical trials, S644
 - for urinary tract infections due to ampicillin- or penicillin-resistant organisms in children, S630
- Sulfamethoxazole, oral, after parenteral sulfamethoxazole/ampicillin for skeletal infections in children, S639
- Suppressor cell, function, regulation and immunosuppression, 941
- Suramin, in treatment of onchocerciasis, 500
- Surgical wound infection, animal model, prophylaxis with sulfamethoxazole/ampicillin, S535
- Surveillance, and infection control, in day care, 613, 631
- Susceptibility testing, for anaerobic bacteria, rationale, 809
- Synergy, antibiotic
 - relation of in vitro to clinical outcome, S305
 - sulfamethoxazole with ampicillin, S528
 - against methicillin-resistant isolates, S549
- Syphilis
 - cultural restrictions on view of venereal and endemic, with emphasis on Russia, 1036
 - endemic, 1036
 - modern and Victorian medical views of, 1036
- Taenia saginata*, case report of persistent infection, 423
- Taeniasis, review of therapy, 423
- Tetanus, control of in developing world, 144
- Tetracyclines, for pelvic inflammatory disease, 86
- Therapy, combination. *See* Combination therapy; *specific drug names*
- Therapy, empiric. *See* Empiric therapy
- Tick-borne infection, spirochetosis, changing research interest, 932
- Tobramycin, with IgG for treatment of *P. aeruginosa* sepsis in mice, S420
- Tolerance
 - to β -lactam antibiotics, S260
 - nongrowing bacteria, lysis, S279
- Toxic shock syndrome, annotated bibliography, S1-S104
 - case reports, S77-S101
 - in languages other than English, S102-S104
 - publications from 1924 through August 1978, S1-S7
 - publications from November 1978 through June 1983, S8-S76
- Toxoplasma gondii*, infections in patients with AIDS, 1001
- Training, in child day care for staff, licensing, and regulatory personnel, 521, 651, 672
- Trauma, infections in wounds caused by corn-harvesting and industrial machines, 927
- Travelers' diarrhea (*see also* Diarrhea; *specific pathogens*)
 - in Africa, S131
 - antimicrobial therapy, S207, S217
 - in Asia, etiology and epidemiology, S136
 - causes, S111
 - chronic, diagnosis and therapy, S223
 - Consensus Development Conference Statement, S227
 - drug therapy, S188
 - due to enterotoxigenic *E. coli*, S131
 - environmental interventions, S142
 - epidemiology, S117, S122, S131, S142, S227
 - etiologic agents, S131
 - fluid and dietary management, S182
 - history of syndrome, S111
 - introduction to consensus conference, S109
 - in Latin America, S131
 - NIH Health Consensus Development Conference, S109-S233
 - nonantibiotic therapy, S202
 - oral rehydration therapy, S182
 - overview of problem, S111
 - prevention, S111, S227
 - prophylaxis, antimicrobial, S160, S167
 - with doxycycline, S160
 - with erythromycin, S160
 - with mecillinam (amdinocillin), S160
 - with trimethoprim-sulfamethoxazole, S167
 - prophylaxis with nonantibiotic drugs, S151
 - resistance of etiologic agents to antimicrobial agents, S172
 - treatment, S111
 - with trimethoprim-sulfamethoxazole or trimethoprim alone, S217
- Treponema pallidum*, clinical manifestations and epidemiology of infection, 760
- Trichinosis
 - historical aspects, 760
 - late complications, 760

- Trichosporon beigeli*, infection, 959
- Trimethoprim, resistance of Enterobacteriaceae, plasmid analysis, 725
- Trimethoprim-sulfamethoxazole
 for infection due to *L. monocytogenes*, case report, 427
 resistance among enteric pathogens, S172
- Tropical disease, myelopathies, etiology, 760
- Trypanosoma cruzi*, biochemistry, molecular biology, and therapy, 884
- Tuberculosis
 extrapulmonary, middle ear, 403
 pituitary gland, 747
- Turista. See Travelers' diarrhea
- Typhoid fever
 diagnosis and bacteriology, 335
 epidemiology and clinical presentation, 330
 historical review, 329
 immunology and prevention, 342
 pathogenesis, 339
 treatment, 341
 with β -lactams and quinolones, 189
 vaccines, 343
- Undernutrition, relation to parasitic infection with *L. donovani*, 447
- Ureaplasma urealyticum*, causing pelvic inflammatory disease, 86
- Urinary tract infection
 aminopenicillin activity against bacterial isolates, S604
 due to ampicillin- or penicillin-resistant organisms in children, treatment with sulbactam/ampicillin, S630
- animal models, due to methicillin-resistant bacteria, treated with sulbactam/ampicillin, S535
 with indwelling catheters, due to *P. stuartii*, 61
 treatment efficacy criteria, S350
- Vaccination. See Immunization
- Vaccines (see also names of specific diseases; Immunization)
 bacterial, new, 573
 Haemophilus influenzae capsular polysaccharide, 558, 568
 hepatitis A and B, development, 591
 not recommended for universal use in children, 573
 OPV vs. IPV, 573
 recommendations to day care providers, 573
 recommended schedule, 573
 ribosomal, microbial, 208
 viral, live, 573
- Vancomycin, for treatment of corynebacterial infection, 42
- Varicella, exclusion from day care, ineffectiveness as control, vaccine, 589
- Vibrio* species, in travelers' diarrhea, S136
- Viral diagnosis, usefulness, 814
- Viral infection, immunosuppression due to, mechanisms, 941
- Waterborne infections, travelers' diarrhea, S142
- Willowbrook hepatitis studies, 157
- Worker's compensation, for day care employees, 644
- Yaws, late complications, 760
- Yersinia enterocolitica* enteritis, treatment, S207

Reviews of Infectious Diseases

Volume 8 • Number 1 • January-February 1986

REVIEW ARTICLES

MICHAEL E. KINGSTON AND DAN MACKEY	Skin Clues in the Diagnosis of Life-Threatening Infections	1
DAVID J. WEBER, KATHLEEN L. HOFFMAN, RICHARD A. THOFT, AND ANN S. BAKER	Endophthalmitis Following Intraocular Lens Implantation: Report of 30 Cases and Review of the Literature	12
MARTIN J. BLASER AND DAVID L. COHN	Opportunistic Infections in Patients with AIDS: Clues to the Epidemiology of AIDS and the Relative Virulence of Pathogens	21
RAMON E. RODRIGUEZ, VICENTE VALERO, AND CHATRCHAI WATANAKUNAKORN	Salmonella Focal Intracranial Infections: Review of the World Literature (1884-1984) and Report of an Unusual Case	31
WILLIAM RIEBEL, NANCY FRANTZ, DAVID ADELSTEIN, AND PHILIP J. SPAGNUOLO	<i>Corynebacterium</i> JK: A Cause of Nosocomial Device-Related Infection	42
ANTHONY L. STOLOFF AND MAREE L. GILLIES	Infections with <i>Eikenella corrodens</i> in a General Hospital: A Re- port of 33 Cases	50
CARMELITA U. TUAZON, VEE GILL, AND FRED GILL	Streptococcal Endocarditis: Single vs. Combination Antibiotic Therapy and Role of Various Species	54
JOHN W. WARREN	<i>Providencia stuartii</i> : A Common Cause of Antibiotic-Resistant Bacteriuria in Patients with Long-Term Indwelling Catheters	61
JEFFERY D. SEMEL	Fever Associated with Repeated Intramuscular Injections of Analgesics	68
DANIEL ROTROSEN, RICHARD A. CALDERONE, AND JOHN E. EDWARDS, JR.	Adherence of <i>Candida</i> Species to Host Tissues and Plastic Surfaces	73
THOMAS G. BURNAKIS AND NANCY B. HILDEBRANDT	Pelvic Inflammatory Disease: A Review with Emphasis on Anti- microbial Therapy	86
LARRY M. BADDOUR AND ALAN L. BISNO	Infective Endocarditis Complicating Mitral Valve Prolapse: Epi- demiologic, Clinical, and Microbiologic Aspects	117

HYPOTHESES

PETER AABY, JETTE BUKH, GERDI HOFF, IDA MARIA LISSE, AND ARJON J. SMITS	Cross-Sex Transmission of Infection and Increased Mortality Due to Measles	138
--	---	-----

SERIAL FEATURES

FRANK SCHOFIELD	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXII. Tetanus: A Preventable Problem	144
-----------------	---	-----

SPECIAL ARTICLE

SAUL KRUGMAN	The Willowbrook Hepatitis Studies Revisited: Ethical Aspects	157
--------------	--	-----

	CLASSICS IN INFECTIOUS DISEASES	
GERHARD DOMAGK	A Contribution to the Chemotherapy of Bacterial Infections	163
	NOTICES	167
	REVIEWERS FOR VOLUME 7	168
	STATEMENT OF EDITORIAL POLICY AND INSTRUCTIONS TO AUTHORS	170

Volume 8 • Supplement 1 • January-February 1986

AN ANNOTATED BIBLIOGRAPHY OF TOXIC SHOCK SYNDROME

Introduction	S1
Papers Published from 1924 through August 1978	S52
Papers Published from November 1978 through June 1985	S58
Case Reports	S77
Papers Published in Languages Other than English	S102

Volume 8 • Number 2 • March-April 1986

REVIEW ARTICLES

PATRICK G. GALLAGHER AND CHATRCHAI WATANAKUNAKORN	Group B Streptococcal Endocarditis: Report of Seven Cases and Review of the Literature, 1962-1985	175
JOE P. BRYAN, HEONIR ROCHA, AND W. MICHAEL SCHELD	Problems in Salmonellosis: Rationale for Clinical Trials with Newer β -Lactam Agents and Quinolones	189
RICHARD L. GREGORY	Microbial Ribosomal Vaccines	208
	THE GLOBAL PROBLEM OF AMEBIASIS: CURRENT STATUS, RESEARCH NEEDS, AND OPPORTUNITIES FOR PROGRESS	
RICHARD L. GUERRANT	Amebiasis: Introduction, Current Status, and Research Questions	218
JULIA A. WALSH	Problems in Recognition and Diagnosis of Amebiasis: Estimation of the Global Magnitude of Morbidity and Mortality	228
GEORGE R. HEALY	Immunologic Tools in the Diagnosis of Amebiasis: Epidemiology in the United States	239
JONATHAN I. RAVDIN	Pathogenesis of Disease Caused by <i>Entamoeba histolytica</i> : Studies of Adherence, Secreted Toxins, and Contact-Dependent Cytolysis	247

ROBERT A. SALATA AND JONATHAN I. RAVDIN	Review of the Human Immune Mechanisms Directed Against <i>Entamoeba histolytica</i>	261
--	--	-----

SERIAL FEATURES

GERALD T. KEUSCH AND NEVIN S. SCRIMSHAW	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXIII. Control of Infection to Reduce the Prevalence of Infantile and Childhood Malnutrition	273
--	--	-----

SPECIAL ARTICLE

HARRY A. FELDMAN	The Meningococcus: A Twenty-Year Perspective	288
------------------	--	-----

EDITORIAL

VICTOR DE GRUTTOLA, KENNETH MAYER, AND WILLIAM BENNETT	AIDS: Has the Problem Been Adequately Assessed?	295
---	---	-----

CORRESPONDENCE

MAX BLOCH	Hookworm Infection	306
-----------	--------------------	-----

	NOTICES	308
--	---------	-----

Volume 8 • Number 3 • May-June 1986

REVIEW ARTICLES

EDWARD S. EISENBERG, IRA LEVITON, AND RUY SOEIRO	Fungal Peritonitis in Patients Receiving Peritoneal Dialysis: Experience with 11 Patients and Review of the Literature	309
---	---	-----

E. E. FREIDIG, S. P. MCCLURE, W. R. WILSON, P. M. BANKS, AND J. A. WASHINGTON II	Clinical-Histologic-Microbiologic Analysis of 419 Lymph Node Biopsy Specimens	322
--	--	-----

ROBERT EDELMAN AND MYRON M. LEVINE	Summary of an International Workshop on Typhoid Fever	329
------------------------------------	---	-----

CHAIWAT TEEKHASAENEE, ROBERT RITCH, AND CHARIMET KANCHANARANYA	Ocular Parasitic Infection in Thailand	350
---	--	-----

GEORGE H. KARAM AND FRANK M. GRIFFIN, JR.	Invasive Pulmonary Aspergillosis in Nonimmunocompromised, Nonneutropenic Hosts	357
--	---	-----

LAWRENCE R. CRANE, DONALD P. LEVINE, MARCUS J. ZERVOS, AND GLENN CUMMINGS	Bacteremia in Narcotic Addicts at the Detroit Medical Center. I. Microbiology, Epidemiology, Risk Factors, and Empiric Therapy	364
--	---	-----

DONALD P. LEVINE, LAWRENCE R. CRANE, AND MARCUS J. ZERVOS	Bacteremia in Narcotic Addicts at the Detroit Medical Center. II. Infectious Endocarditis: A Prospective Comparative Study	374
--	---	-----

A. E. SIMOR, M. A. KARMALI, T. JADAVJI, AND M. ROSCOE	Abortion and Perinatal Sepsis Associated with <i>Campylobacter</i> Infection	397
--	---	-----

PAUL R. SKOLNIK, JOSEPH B. NADOL, JR., AND ANN SULLIVAN BAKER	Tuberculosis of the Middle Ear: Review of the Literature with an Instructive Case Report	403
--	---	-----

DAVID CHARLES AND BRYAN LARSEN	Streptococcal Puerperal Sepsis and Obstetric Infections: A Historical Perspective	411
--------------------------------	--	-----

CLINICAL NOTES

STEN H. VERMUND, SHEILA MACLEOD, AND ROBERT G. GOLDSTEIN	Taeniasis Unresponsive to a Single Dose of Niclosamide: Case Report of Persistent Infection with <i>Taenia saginata</i> and a Review of Therapy	423
---	---	-----

PETER G. SPITZER, SCOTT M. HAMMER, AND ADOLF W. KARCHMER	Treatment of <i>Listeria monocytogenes</i> Infection with Trimethoprim-Sulfamethoxazole: Case Report and Review of the Literature	427
YECHESKEL SAMRA, YECHIEL SHAKED, AND MICHAEL K. MAIER	Nontyphoid Salmonellosis in Renal Transplant Recipients: Report of Five Cases and Review of the Literature	431
GABRIEL MORDUCHOWICZ, DAN SHMUELI, ZACHI SHAPIRA, SIMON L. COHEN, ALEX YUSSIM, COLIN S. BLOCK, JOSEPH B. ROSENFELD, AND SILVIO D. PITLIK	Rhinocerebral Mucormycosis in Renal Transplant Recipients: Report of Three Cases and Review of the Literature	441
HYPOTHESIS		
LEE H. HARRISON, TALAPALA G. NAIDU, JEAN S. DREW, JOAQUIM EDUARDO DE ALENCAR, AND RICHARD D. PEARSON	Reciprocal Relationship Between Undernutrition and the Parasitic Disease Visceral Leishmaniasis	447
SERIAL FEATURES		
TRENTON K. RUEBUSH II, JOEL G. BREMAN, ROBERT L. KAISER, AND MCWILSON WARREN	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXIV. Malaria	454
WILLIAM H. FOEGE AND DONALD A. HENDERSON	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXV. Management Priorities in Primary Health Care.	467
HAROLD C. NEU	Controversies in the Diagnosis and Management of Infectious Diseases: Introduction to the Series	476
SESSION I: REIMBURSEMENT FOR HEALTH CARE		
ROBERT G. PETERSDORF	Training, Cost Containment, and Practice: Effect on Infectious Diseases	478
RONALD J. MOLESKI AND VINCENT T. ANDRIOLE	Role of the Infectious Disease Specialist in Containing Costs of Antibiotics in the Hospital	488
DAVID W. GITCH	New Ways of Managing Under Prospective Payment and Their Impact on the Principles and Practice of Infectious Diseases	494
MARVIN TURCK	Summary of the Panel on Reimbursement for Health Care: Controversies Concerning the Impact on Training and Practice	499
EDITORIAL		
MOHAMMED A. AZIZ	Chemotherapeutic Approach to Control of Onchocerciasis	500
CLASSICS IN INFECTIOUS DISEASES		
NATHAN SMITH	Observations on the Pathology and Treatment of Necrosis	505
NOTICES		511

TRAVELERS' DIARRHEA: NATIONAL INSTITUTES OF
HEALTH CONSENSUS DEVELOPMENT CONFERENCE

Participants

v

SHERWOOD L. GORBACH AND ROBERT EDELMAN	Introduction	S109
	I. OVERVIEW	
B. H. KEAN	Travelers' Diarrhea: An Overview	S111
	II. EPIDEMIOLOGY AND ETIOLOGY	
KRISTINE L. MACDONALD AND MITCHELL L. COHEN	Epidemiology of Travelers' Diarrhea: Current Perspectives	S117
ROBERT STEFFEN	Epidemiologic Studies of Travelers' Diarrhea, Severe Gastrointestinal Infections, and Cholera	S122
ROBERT E. BLACK	Pathogens That Cause Travelers' Diarrhea in Latin America and Africa	S131
DAVID N. TAYLOR AND PETER ECHEVERRIA	Etiology and Epidemiology of Travelers' Diarrhea in Asia	S136
	III. PREVENTION	
MARTIN J. BLASER	Environmental Interventions for the Prevention of Travelers' Diarrhea	S142
ROBERT STEFFEN, ROLF HEUSSER, AND HERBERT L. DUPONT	Prevention of Travelers' Diarrhea by Nonantibiotic Drugs	S151
R. BRADLEY SACK	Antimicrobial Prophylaxis of Travelers' Diarrhea: A Selected Summary	S160
HERBERT L. DUPONT, CHARLES D. ERICSSON, PHILIP C. JOHNSON, AND FRANCISCO J. CABADA	Antimicrobial Agents in the Prevention of Travelers' Diarrhea	S167
BARBARA E. MURRAY	Resistance of <i>Shigella</i> , <i>Salmonella</i> , and Other Selected Enteric Pathogens to Antimicrobial Agents	S172
	IV. TREATMENT	
JOHN G. BANWELL	Treatment of Travelers' Diarrhea: Fluid and Dietary Management	S182
MARK DONOWITZ, JOAN WICKS, AND GEOFFREY W. G. SHARP	Drug Therapy for Diarrheal Diseases: A Look Ahead	S188
CHARLES D. ERICSSON, HERBERT L. DUPONT, AND PHILIP C. JOHNSON	Nonantibiotic Therapy for Travelers' Diarrhea	S202
MYRON M. LEVINE	Antimicrobial Therapy for Infectious Diarrhea	S207
HERBERT L. DUPONT, CHARLES D. ERICSSON, RANDALL R. REVES, AND EMMA GALINDO	Antimicrobial Therapy for Travelers' Diarrhea	S217

RALPH A. GIANNELLA	Chronic Diarrhea in Travelers: Diagnostic and Therapeutic Considerations	S223
--------------------	--	------

V. CONSENSUS DEVELOPMENT CONFERENCE STATEMENT	S227
---	------

Volume 8 • Supplement 3 • July-August 1986

EVALUATION OF NEW β -LACTAM ANTIBIOTICS

S. RAGNAR NORRBY	Evaluation of New β -Lactam Antibiotics: Introduction and Summary	S235
------------------	---	------

I. BASIC EVALUATION OF NEW β -LACTAM ANTIBIOTICS

HAROLD C. NEU	β -Lactam Antibiotics: Structural Relationships Affecting in Vitro Activity and Pharmacologic Properties	S237
ALEXANDER TOMASZ	Penicillin-Binding Proteins and the Antibacterial Effectiveness of β -Lactam Antibiotics	S260
ELAINE TUOMANEN	Phenotypic Tolerance: The Search for β -Lactam Antibiotics That Kill Nongrowing Bacteria	S279
FREDERIK LINDBERG AND STAFFAN NORMARK	Contribution of Chromosomal β -Lactamases to β -Lactam Resistance in Enterobacteria	S292

II. EVALUATION OF IN VITRO AND IN VIVO EFFICACY OF NEW β -LACTAM ANTIBIOTICS

STIG E. HOLM	Interaction Between β -Lactam and Other Antibiotics	S305
J. LOUISE GERBERDING AND MERLE A. SANDE	Limitations of Animal Models in Predicting β -Lactam Efficacy for Endocarditis and Meningitis	S315

III. PHARMACOKINETIC EVALUATION OF NEW β -LACTAM ANTIBIOTICS

TOM BERGAN	Requirements for Pharmacokinetic Evaluation of Antibiotics in Phase I Studies	S319
RICHARD WISE	Methods for Evaluating the Penetration of β -Lactam Antibiotics into Tissues	S325

IV. CLINICAL EVALUATION OF NEW β -LACTAM ANTIBIOTICS

A. M. GEDDES	Studies of β -Lactam Antibiotics in Systemic Infections: Some Personal Observations over 25 Years	S333
LOWELL S. YOUNG	Problems of Studying Infections in the Compromised Host	S341
BERNHARD HUITFELDT	Statistical Aspects of Clinical Trials of Antibiotics in Acute Infections	S350
S. RAGNAR NORRBY	Problems in Evaluation of Adverse Reactions to β -Lactam Antibiotics	S358

INFECTIOUS DISEASES IN CHILD DAY CARE:
MANAGEMENT AND PREVENTION

MICHAEL T. OSTERHOLM, JEROME O. KLEIN, SUSAN S. ARONSON, AND LARRY K. PICKERING	Introduction	513
I. CHILD DAY CARE AND INFECTIOUS DISEASE: AN OVERVIEW		
EDWARD ZIGLER AND SUSAN MUENCHOW	Infectious Diseases in Day Care: Parallels Between Psychologically and Physically Healthy Care	514
JEROME O. KLEIN	Infectious Diseases and Day Care	521
II. CLINICAL AND EPIDEMIOLOGIC ASPECTS OF INFECTIOUS DISEASES IN CHILD DAY CARE		
FLOYD W. DENNY, ALBERT M. COLLIER, AND FREDERICK W. HENDERSON	Acute Respiratory Infections in Day Care	527
FREDERICK W. HENDERSON AND G. SCOTT GIEBINK	Otitis Media Among Children in Day Care: Epidemiology and Pathogenesis	533
LARRY K. PICKERING, ALFRED V. BARTLETT, AND WILLIAM E. WOODWARD	Acute Infectious Diarrhea Among Children in Day Care: Epidemiol- ogy and Control	539
STEPHEN C. HADLER AND LOUISE MCFARLAND	Hepatitis in Day Care Centers: Epidemiology and Prevention	548
ROBERT S. DAUM, DAN M. GRANOFF, JANET GILSDORF, TRUDY MURPHY, AND MICHAEL T. OSTERHOLM	<i>Haemophilus influenzae</i> Type b Infections in Day Care Attendees: Implications for Management	558
DAVID W. FLEMING, STEPHEN L. COCHI, HARRY F. HULL, STEVEN D. HELGERSON, DAVID R. CUNDIFF, AND CLAIRE V. BROOME	Prevention of <i>Haemophilus influenzae</i> Type b Infections in Day Care: A Public Health Perspective	568
ALAN R. HINMAN	Vaccine-Preventable Diseases and Child Day Care	573
CLAIRE V. BROOME	Use of Bacterial Vaccines for Prevention of Pneumococcal and Meningococcal Disease in the Day Care Setting	584
PHILIP A. BRUNELL, JEAN TAYLOR-WIEDEMAN, AND ALAN W. LIEVENS	Varicella in Day Care Centers	589
ARLENE A. MCLEAN	Development of Vaccines Against Hepatitis A and Hepatitis B	591
ROBERT F. PASS AND CECILIA HUTTO	Group Day Care and Cytomegaloviral Infections of Mothers and Children	599
KRISTINE L. MACDONALD, RICHARD N. DANILA, AND MICHAEL T. OSTERHOLM	Infection with Human T-Lymphotropic Virus Type III/Lympha- denopathy-Associated Virus: Considerations for Transmission in the Child Day Care Setting	606
III. DISEASE PREVENTION POLICIES AND PRACTICES FOR DAY CARE OPERATION		
JEFFREY P. DAVIS AND JEANNE A. PFEIFFER	Surveillance of Communicable Diseases in Child Day Care Settings	613

NORMAN J. PETERSEN AND GARY K. BRESSLER	Design and Modification of the Day Care Environment	618
EUGENE D. SHAPIRO, JOEL KURITSKY, AND JO POTTER	Policies for the Exclusion of Ill Children from Group Day Care: An Unresolved Dilemma	622
ALICE E. JORDAN	The Unresolved Child Care Dilemma: Care for the Acutely Ill Child	626
RICHARD A. GOODMAN, MARY P. GLODE, JEANNE A. PFEIFFER, AND JANE C. GRADY	A Role for the Infection Control Specialist in Child Day Care?	631
IV. CHILD DAY CARE REGULATION AND LEGAL RELATIONSHIP TO INFECTIOUS DISEASES		
GWEN G. MORGAN, CAROL S. STEVENSON, RICHARD FIENE, AND KEITH O. STEPHENS	Gaps and Excesses in the Regulation of Child Day Care: Report of a Panel	634
CAROL S. STEVENSON, GEORGE S. STERNE, AND KEITH O. STEPHENS	Liability for Infectious Diseases in Day Care: Legal and Practical Considerations	644
V. TRAINING FOR PARENTS, CHILD DAY CARE PROVIDERS, REGULATORS, AND PUBLIC HEALTH PERSONNEL		
JUDITH A. CALDER AND JUDITH LINDMAN	Resources Related to Infectious Illness for Child Care Providers	648
EARLINE D. KENDALL, SUSAN S. ARONSON, SALLY GOLDBERG, AND HERBERTA SMITH	Training for Child Day Care Staff and for Licensing and Regula- tory Personnel in the Prevention of Disease Transmission	651
HERBERTA SMITH AND SUSAN S. ARONSON	Organizational Approach to Medication Administration in Day Care	657
GEORGE G. STERNE, ALAN HINMAN, AND SUSAN SCHMID	Potential Health Benefits of Child Day Care Attendance	660
ALFRED V. BARTLETT, PHOEBE ORTON, AND MARION TURNER	Day Care Homes: The "Silent Majority" of Child Day Care	663
RICHARD A. GOODMAN, LETTY A. LIE, SELMA R. DEITCH, AND CRAIG W. HEDBERG	Relationship Between Day Care and Health Care Providers	669
VI. SUMMARY		
SUSAN S. ARONSON AND MICHAEL T. OSTERHOLM	Infectious Diseases in Child Day Care: Management and Prevention. Summary of the Symposium and Recommendations	672

Volume 8 • Supplement 4 • July-August 1986

PROPERTIES AND CHARACTERISTICS OF A NEW IMMUNOGLOBULIN G INTRAVENOUS PREPARATION

	Participants	v
JAMES E. PENNINGTON	Properties and Characteristics of a New Immunoglobulin G Intra- venous Preparation: Introduction to the Symposium	S371
J. P. McCUE, R. H. HEIN, AND R. TENOLD	Three Generations of Immunoglobulin G Preparations for Clinical Use	S374
J. L. LUNDBLAD, G. MITRA, M. M. STERNBERG, AND D. D. SCHROEDER	Comparative Studies of Impurities in Intravenous Immunoglobulin Preparations	S382

DOUGLAS C. HEINER	IgG Subclass Composition of Intravenous Immunoglobulin Preparations: Clinical Relevance	S391
HARRY R. HILL AND JAMES M. BATHRAS	Protective and Opsonic Activities of a Native, pH 4.25 Intravenous Immunoglobulin G Preparation Against Common Bacterial Pathogens	S396
THOMAS E. HARPER, ROBERT D. CHRISTENSEN, GERALD ROTHSTEIN, AND HARRY R. HILL	Effect of Intravenous Immunoglobulin G on Neutrophil Kinetics During Experimental Group B Streptococcal Infection in Neonatal Rats	S401
THOMAS E. EMERSON, JR., MICHAEL S. COLLINS, AND MIRIAM D. BUDINGER	Use of a New, Low-pH Immunoglobulin G Preparation During Episodes of Bacteremia in the Rat	S409
MICHAEL S. COLLINS, GRACE C. TSAY, RICHARD F. HECTOR, ROBERT E. ROBY, AND JOE H. DORSEY	Immunoglobulin G: Potentiation of Tobramycin and Azlocillin in the Treatment of <i>Pseudomonas aeruginosa</i> Sepsis in Neutropenic Mice and Neutralization of Exotoxin A in Vivo	S420
JAMES E. PENNINGTON, GERALD B. PIER, JERALD C. SADOFF, AND GLORIA J. SMALL	Active and Passive Immunization Strategies for <i>Pseudomonas aeruginosa</i> Pneumonia	S426
ROBERT B. LEWIS, DEBBIE S. MATZKE, THOMAS B. ALBRECHT, AND RICHARD B. POLLARD	Assessment of the Presence of Cytomegalovirus-Neutralizing Antibody by a Plaque-Reduction Assay	S434
KIM S. ERLICH AND JOHN MILLS	Passive Immunotherapy for Encephalitis Caused by Herpes Simplex Virus	S439
STEVE KOHL AND LIAN SIM LOO	In Vitro and in Vivo Antibody-Dependent Cellular Cytotoxicity of Intravenous Immunoglobulin G Preparations Against Herpes Simplex Virus	S446
RICHARD I. SCHIFF	Half-Life and Clearance of pH 6.8 and pH 4.25 Immunoglobulin G Intravenous Preparations in Patients with Primary Disorders of Humoral Immunity	S449
BERNARD PIROFSKY	Safety and Toxicity of a New Serum Immunoglobulin G Intravenous Preparation, IGIV pH 4.25	S457

Volume 8 • Number 5 • September-October 1986

ADVANCES IN MOLECULAR EPIDEMIOLOGY

DAVID M. SHLAES AND JOSEPH F. JOHN, JR.	Introduction	681
KAYE WACHSMUTH	Molecular Epidemiology of Bacterial Infections: Examples of Methodology and of Investigations of Outbreaks	682
JOSEPH F. JOHN, JR., AND JAMES A. TWITTY	Plasmids as Epidemiologic Markers in Nosocomial Gram-Negative Bacilli: Experience at a University and Review of the Literature	693
DENNIS R. SCHABERG AND MARCUS ZERVOS	Plasmid Analysis in the Study of the Epidemiology of Nosocomial Gram-Positive Cocci	705
J. BRUNTON, D. CLARE, AND M. A. MEIER	Molecular Epidemiology of Antibiotic Resistance Plasmids of <i>Haemophilus</i> Species and <i>Neisseria gonorrhoeae</i>	713
F. W. GOLDSTEIN, B. PAPADOPOULOU, AND J. F. ACAR	The Changing Pattern of Trimethoprim Resistance in Paris, with a Review of Worldwide Experience	725

DAVID M. SHLAES AND C. A. CURRIE-McCUMBER	Plasmid Analysis in Molecular Epidemiology: A Summary and Future Directions	738
REVIEW ARTICLES		
STEPHEN A. BERGER, STEPHEN C. EDBERG, AND GWEN DAVID	Infectious Disease in the Sella Turcica	747
STEPHEN A. BERGER	Antimicrobial Agents and the Medical Journal: Trends in Publish- ing, 1936-1983	756
GUSTAVO C. ROMÁN AND LYDIA N. ROMÁN	Occurrence of Congenital, Cardiovascular, Visceral, Neurologic, and Neuro-Ophthalmologic Complications in Late Yaws: A Theme for Future Research.	760
CLINICAL NOTES		
JAY I. SUSSMAN, ELLEN J. BARON, STEVEN M. GOLDBERG, MARK H. KAPLAN, AND ROY A. PIZZARELLO	Clinical Manifestations and Therapy of Lactobaccillus Endocarditis: Report of a Case and Review of the Literature.	771
CRAIG A. FRIESEN AND CHENG T. CHO	Characteristic Features of Neonatal Sepsis Due to <i>Haemophilus</i> <i>influenzae</i>	777
STEVEN M. OPAL, L. BARTH RELLER, GERALD HARRINGTON, AND PRESTON CANNADY, JR.	<i>Aspergillus clavatus</i> Endocarditis Involving a Normal Aortic Valve Following Coronary Artery Surgery	781
WILLIAM G. POWDERLY, SAMUEL L. STANLEY, JR., AND GERALD MEDOFF	Pneumococcal Endocarditis: Report of a Series and Review of the Literature	786
SERIAL FEATURES		
CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF INFECTIOUS DISEASES. SESSION II: DIAGNOSIS		
JOHN A. WASHINGTON II AND DUANE M. ILSTRUP	Blood Cultures: Issues and Controversies	792
L. BARTH RELLER	The Serum Bactericidal Test	803
ROBERT M. SWENSON	Rationale for Identification and Susceptibility Testing of Anaerobic Bacteria	809
W. LAWRENCE DREW	Controversies in Viral Diagnosis	814
JOHN A. WASHINGTON II	Controversies in the Diagnosis and Management of Infectious Diseases. Session II: Diagnosis. Summary and Discussion	825
CORRESPONDENCE		
H. R. INGHAM AND P. R. SISSON	Microbial Synergy	828
ORI D. ROTSTEIN, TIMOTHY L. PRUETT, AND RICHARD L. SIMMONS	Reply	829
ALAN WATKINS	Risk for Congenital Rubella	830
LESLIE GROSINGER AND CARL B. LAUTER	Salmonella Subdural Empyema in a Patient with Brain Metastasis	830

CLASSICS IN INFECTIOUS DISEASES

CHESTER S. KEEFER, FRANZ J. INGELFINGER, AND WESLEY W. SPINK	Significance of Hemolytic Streptococcal Bacteremia: A Study of Two Hundred and Forty-Six Patients	832
--	---	-----

NOTICES	838
---------	-----

ERRATUM (8:309-21)	839
--------------------	-----

Volume 8 • Number 6 • November-December 1986

REVIEW ARTICLES

KERRY R. EMSLIE AND SYDNEY NADE	Pathogenesis and Treatment of Acute Hematogenous Osteomyelitis: Evaluation of Current Views with Reference to an Animal Model	841
BARRY T. ROUSE AND DAVID W. HOROHV	Immunosuppression in Viral Infections	850
KEN TOKUGAWA, KOHJI UEDA, JUNICHIRO FUKUSHIGE, TAKASHI KOYANAGI, AND SACHIO HISANAGA	Congenital Rubella Syndrome and Physical Growth: A 17-Year, Prospective, Longitudinal Follow-Up in the Ryukyu Islands	874
J. JOSEPH MARR AND ROBERTO DOCAMPO	Chemotherapy for Chagas' Disease: A Perspective of Current Therapy and Considerations for Future Research	884
PRANATHARTHI H. CHANDRASEKAR AND AMRIT P. NARULA	Bone and Joint Infections in Intravenous Drug Abusers	904
ABRAHAM VERGHESE, KATHLEEN MIREAULT, AND ROBERT D. ARBEIT	Group B Streptococcal Bacteremia in Men	912
JOHN F. MODLIN	Perinatal Echovirus Infection: Insights from a Literature Review of 61 Cases of Serious Infection and 16 Outbreaks in Nurseries	918
WILLIAM A. AGGER, THOMAS H. COGBILL, HENRY BUSCH, JR., JEFFREY LANDERCASPER, AND STEVEN M. CALLISTER	Wounds Caused by Corn-Harvesting Machines: An Unusual Source of Infection Due to Gram-Negative Bacilli	927
WILLY BURGDORFER	The Enlarging Spectrum of Tick-Borne Spirochetoses: R. R. Parker Memorial Address	932
MARK R. BIBLER AND GREGORY W. ROUAN	Cryptogenic Group A Streptococcal Bacteremia: Experience at an Urban General Hospital and Review of the Literature	941

CLINICAL NOTES

RICHARD K. COCHRAN, CARL L. PIERSON, THOMAS L. SELL, AND THOMAS PALELLA	Protothecal Olecranon Bursitis: Treatment with Intrabursal Amphotericin B	952
PETER RONEY, CHARLES C. BARR, CHIN HAK CHUN, AND MARTIN J. RAFF	Endogenous Aspergillus Endophthalmitis	955
JENNIFER HOY, KUO-CHING HSU, KENNETH ROLSTON, ROY L. HOPFER, MARIO LUNA, AND GERALD P. BODEY	<i>Trichosporon beigeli</i> Infection: A Review	959
ROBERT R. DEE AND BENNETT LORBER	Brain Abscess Due to <i>Listeria monocytogenes</i> : Case Report and Literature Review	968
YECHESKEL SAMRA, YECHIEL SHAKED, AND MICHAEL K. MAIER	Nontyphoid Salmonellosis in Patients with Total Hip Replacement: Report of Four Cases and Review of the Literature	978

INTERNATIONAL NOTES

SHIH YING AND CHAO SHUYAN	Botulism in China	984
---------------------------	-------------------	-----

SERIAL FEATURES

CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF INFECTIOUS DISEASES. SESSION III: AIDS

MARKUS VOGT AND MARTIN S. HIRSCH	Prospects for the Prevention and Therapy of Infections with the Human Immunodeficiency Virus	991
JOHN MILLS	<i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> Infections in Patients with AIDS	1001
ROSEMARY SOAVE AND DONALD ARMSTRONG	<i>Cryptosporidium</i> and Cryptosporidiosis	1012
LOWELL S. YOUNG, CLARK B. INDERLIED, O. GEORGE BERLIN, AND MICHAEL S. GOTTLIEB	Mycobacterial Infections in AIDS Patients, with an Emphasis on the <i>Mycobacterium avium</i> Complex	1024
MERLE A. SANDE	Controversies in the Diagnosis and Management of Infectious Diseases. Session III: AIDS. Summary and Discussion	1034

HISTORICAL ARTICLE

LAURA ENGELSTEIN	Syphilis, Historical and Actual: Cultural Geography of a Disease	1036
------------------	--	------

NOTICES	1049
---------	------

ERRATUM (1985;7:S783-8)	1050
-------------------------	------

INDEXES TO VOLUME 8

Author Index	1051
Subject Index	1054
Contents for Volume 8	1067

Volume 8 • Supplement 5 • November-December 1986

ENZYME-MEDIATED RESISTANCE TO β -LACTAM ANTIBIOTICS: A SYMPOSIUM ON SULBACTAM/AMPICILLIN

EDWARD H. KASS AND HARTMUT LODE	Symposium on Sulbactam/Ampicillin: Introduction and Summary	S465
	I. β -LACTAMASES AND β -LACTAM ANTIBIOTICS	
A. BAUERNFEIND	Classification of β -Lactamases	S470
J. F. ACAR AND C. MINOZZI	Role of β -Lactamases in the Resistance of Gram-Negative Bacilli to β -Lactam Antibiotics	S482
DAVID GREENWOOD	An Overview of the Response of Bacteria to β -Lactam Antibiotics	S487
	II. PHARMACOKINETICS AND PHARMACOLOGY	
ROGER LABIA, ANNICK MORAND, VERONIQUE LELIEVRE, DORIANE MATTIONI, AND ANTOINE KAZMIERCZAK	Sulbactam: Biochemical Factors Involved in Its Synergy with Ampicillin	S496

GEORGE FOULDS	Pharmacokinetics of Sulbactam/Ampicillin in Humans: A Review	S503
URS B. SCHAAD, KATHRIN GUENIN, AND PETER STRAEHL	Single-Dose Pharmacokinetics of Intravenous Sulbactam in Pediatric Patients	S512
A. M. SUTTON, T. L. TURNER, F. COCKBURN, AND T. A. McALLISTER	Pharmacokinetic Study of Sulbactam and Ampicillin Administered Concomitantly by Intraarterial or Intravenous Infusion in the Newborn	S518
R. F. MUSHINSKY, M. L. REYNOLDS, C. A. NICHOLSON, L. L. CRIDER, AND G. A. FORCIER	Stability of Sulbactam/Ampicillin in Diluents for Parenteral Administration	S523
III. IN VITRO STUDIES OF SUSCEPTIBILITY AND RESISTANCE AND ANIMAL MODELS OF INFECTION		
J. A. RETSEMA, A. R. ENGLISH, A. GIRARD, J. E. LYNCH, M. ANDERSON, L. BRENNAN C. CIMOCHOWSKI, J. FAIELLA, W. NORCIA, AND P. SAWYER	Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection	S528
A. R. ENGLISH, D. GIRARD, C. CIMOCHOWSKI, J. FAIELLA, J. A. RETSEMA, AND J. E. LYNCH	Activity of Sulbactam/Ampicillin in Screening and Discriminative Animal Models of Infection	S535
CARL ERIK NORD	Mechanisms of β -Lactam Resistance in Anaerobic Bacteria	S543
ANTOINE KAZMIERCZAK, JEAN-MARIE DUEZ, ANDRÉ PECHINOT, PATRICE NORDMANN, AND ROGER LABIA	In Vitro Bactericidal Activity of Sulbactam plus Ampicillin Against Methicillin-Resistant <i>Staphylococcus aureus</i>	S549
J. D. WILLIAMS AND F. MOOSDEEN	Antibiotic Resistance in <i>Haemophilus influenzae</i> : Epidemiology, Mechanisms, and Therapeutic Possibilities	S555
F. MOOSDEEN, J. KEEBLE, AND J. D. WILLIAMS	Induction/Inhibition of Chromosomal β -Lactamases by β -Lactamase Inhibitors	S562
IV. CLINICAL STUDIES		
GENERAL		
JOHN F. REINHARDT, LYNN JOHNSTON, PETER RUANE, CAROLINE C. JOHNSON, LESLIE INGRAM-DRAKE, KEITH MACDONALD, KEVIN W. WARD, GLENN MATHISEN, W. LANCE GEORGE, SYDNEY M. FINEGOLD, AND MAURY E. MULLIGAN	A Randomized, Double-Blind Comparison of Sulbactam/Ampicillin and Clindamycin for the Treatment of Aerobic and Anaerobic Infections	S569
OBSTETRIC AND GYNECOLOGIC INFECTIONS		
KENNETH T. KROHN	Effect of Prophylactic Administration of Sulbactam/Ampicillin on the Rate of Postoperative Endometritis After First-Trimester Abortion	S576
HELEN GIAMARELLOU, GEORGE TROUVAS, ATHINA AVLAMI, DIONYSIS ARAVANTINOS, AND GEORGE K. DAIKOS	Efficacy of Sulbactam plus Ampicillin in Gynecologic Infections	S579
INTRAABDOMINAL INFECTIONS		
STUDY GROUP OF INTRAABDOMINAL INFECTIONS	A Randomized Controlled Trial of Ampicillin plus Sulbactam vs. Gentamicin plus Clindamycin in the Treatment of Intraabdominal Infections: A Preliminary Report	S583

DAVID L. MORRIS, CHARANJEIT S. UBHI, CHARLES S. ROBERTSON, AND KEITH W. BRAMMER	Biliary Pharmacokinetics of Sulbactam plus Ampicillin in Humans	S589
SOFT TISSUE AND BONE AND JOINT INFECTIONS		
L. LÖFFLER, A. BAUERNFEIND, W. KEYL, B. HOFFSTEDT, A. PIERGIES, AND W. LENZ	An Open, Comparative Study of Sulbactam plus Ampicillin vs. Cefotaxime as Initial Therapy for Serious Soft Tissue and Bone and Joint Infections	S593
URINARY TRACT INFECTIONS		
JOONGH-HWAN KIM, KWANG-HO CHOI, YOUNG-TAE KIM, AND IN-SUB YANG	Treatment of Infections Due to Multiresistant <i>Neisseria gonorrhoeae</i> with Sulbactam/Ampicillin	S599
K. G. NABER AND R. WITTENBERGER	In Vitro Activity of Aminopenicillins Combined with Sulbactam, Clavulanic Acid, or Amdinocillin Against Bacteria Isolated from Patients with Complicated Urinary Tract Infections	S604
CENTRAL NERVOUS SYSTEM		
PENTTI HÄNNINEN AND TUIRE ROSSI	Penetration of Sulbactam into Cerebrospinal Fluid of Patients with Viral Meningitis or without Meningitis	S609
JEAN-PAUL STAHL, JEAN-PIERRE BRU, GILLES FREDJ, KEITH W. BRAMMER, MARIE-REINE MALLERET, AND MAX MICOUD	Penetration of Sulbactam into the Cerebrospinal Fluid of Patients with Bacterial Meningitis Receiving Ampicillin Therapy	S612
PEDIATRIC INFECTIONS		
ELLEN WALD, JAMES S. REILY, CHARLES D. BLUESTONE, AND DARLEEN CHIPONIS	Sulbactam/Ampicillin in the Treatment of Acute Epiglottitis in Children	S617
WILLIAM J. RODRIGUEZ, WAHEED N. KHAN, JOSE PUIG, JESUS FERIS, SANDRA HARMON, BESS G. GOLD, AND SHAMA AHMAD	Sulbactam/Ampicillin vs. Chloramphenicol/Ampicillin for the Treatment of Meningitis in Infants and Children	S620
VASSILIKI SYRIOPOULOU, MARGARITA BITSI, CHARALAMBOS THEODORIDIS, IRENE SAROGLOU, XENOFON KRIKOS, AND KONSTANTINA TZANETOU	Clinical Efficacy of Sulbactam/Ampicillin in Pediatric Infections Caused by Ampicillin-Resistant or Penicillin-Resistant Organisms	S630
M. C. FOSTER, LEELA KAPILA, D. L. MORRIS, AND R. C. B. SLACK	A Randomized Comparative Study of Sulbactam plus Ampicillin vs. Metronidazole plus Cefotaxime in the Management of Acute Appendicitis in Children	S634
STEPHEN C. ARONOFF, PETER V. SCOLES, JOHN T. MAKLEY, MICHAEL R. JACOBS, JEFFREY L. BLUMER, AND ALI KALAMCHI	Efficacy and Safety of Sequential Treatment with Parenteral Sulbactam/Ampicillin and Oral Sultamicillin for Skeletal Infections in Children	S639
OVERVIEW		
L. LEES, J. A. MILSON, A. K. KNIRSCH, AND K. GREENHALGH	Sulbactam plus Ampicillin: Interim Review of Efficacy and Safety for Therapeutic and Prophylactic Use	S644

